Efficacy of Ketorolac 0.4% in Prostaglandin Suppression

Allergan

Status and phase: Completed; Phase 4

Conditions: Inflammation

Treatments: Drug: Ketorolac 0.4%; Drug: Lubricating Eye Drop

Study type: Interventional

Funder types: Industry

Identifiers

NCT00791323

MA-ACU-08-001

Details and patient eligibility

About

A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy

Enrollment: 9 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients scheduled to undergo phakic IOL implantation

Exclusion criteria

• History of intraocular surgery in the operative eye

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

9 participants in 2 patient groups

1

Active Comparator group

Description:

Ketorolac 0.4%

Treatment:

Drug: Ketorolac 0.4%

2

Active Comparator group

Description:

Mineral Oil Emollient

Treatment:

Drug: Lubricating Eye Drop